Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
28.01
-0.50 (-1.77%)
At close: Jul 6, 2026, 4:00 PM EDT
27.65
-0.36 (-1.29%)
After-hours: Jul 6, 2026, 7:55 PM EDT
Genmab Revenue
Genmab had revenue of $896.00M in the quarter ending March 31, 2026, with 25.31% growth. This brings the company's revenue in the last twelve months to $3.90B, up 27.49% year-over-year. In the year 2025, Genmab had annual revenue of $3.72B with 19.19% growth.
Revenue (ttm)
$3.90B
Revenue Growth
+27.49%
P/S Ratio
4.39
Revenue / Employee
$1,263,277
Employees
3,088
Market Cap
17.14B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.72B | 599.00M | 19.19% |
| Dec 31, 2024 | 3.12B | 731.00M | 30.59% |
| Dec 31, 2023 | 2.39B | 302.26M | 14.48% |
| Dec 31, 2022 | 2.09B | 800.56M | 62.19% |
| Dec 31, 2021 | 1.29B | -372.56M | -22.45% |
| Dec 31, 2020 | 1.66B | 854.42M | 106.10% |
| Dec 31, 2019 | 805.32M | 340.75M | 73.35% |
| Dec 31, 2018 | 464.57M | 83.44M | 21.89% |
| Dec 31, 2017 | 381.13M | 123.38M | 47.87% |
| Dec 31, 2016 | 257.75M | 92.65M | 56.12% |
| Dec 31, 2015 | 165.10M | 26.80M | 19.38% |
| Dec 31, 2014 | 138.30M | 15.94M | 13.02% |
| Dec 31, 2013 | 122.37M | 36.66M | 42.77% |
| Dec 31, 2012 | 85.70M | 24.59M | 40.23% |
| Dec 31, 2011 | 61.12M | -43.27M | -41.45% |
| Dec 31, 2010 | 104.39M | -8.77M | -7.75% |
| Dec 31, 2009 | 113.16M | -16.25M | -12.56% |
| Dec 31, 2008 | 129.42M | 25.30M | 24.29% |
| Dec 31, 2007 | 104.12M | 80.20M | 335.29% |
| Dec 31, 2006 | 23.92M | 8.33M | 53.41% |
| Dec 31, 2005 | 15.59M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.36B |
| Jazz Pharmaceuticals | 4.44B |
| BioNTech SE | 3.23B |
| Exelixis | 2.38B |
| Ionis Pharmaceuticals | 1.06B |
| Ascendis Pharma | 998.25M |
| Insmed | 819.56M |
| Axsome Therapeutics | 708.24M |
GMAB News
- 11 hours ago - Genmab says EC grants marketing authorization for Tepkinly combo - TheFly
- 12 hours ago - Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire
- 4 days ago - Genmab price target raised to $40 from $38 at H.C. Wainwright - TheFly
- 6 days ago - Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial - WSJ
- 7 days ago - Genmab (GMAB) Reports Positive Phase 3 Trial Results for Epcoritamab - GuruFocus
- 7 days ago - Genmab announces topline results from EPCORE DLBCL-4 trial - TheFly
- 7 days ago - Genmab reports ‘positive’ Phase 3 results from EPCORE DLBCL-4 trial - TheFly
- 7 days ago - Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival - GlobeNewsWire